Short Interest in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Grows By 80.0%

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) saw a large growth in short interest during the month of September. As of September 15th, there was short interest totalling 364,600 shares, a growth of 80.0% from the August 31st total of 202,500 shares. Based on an average daily volume of 5,550,000 shares, the days-to-cover ratio is currently 0.1 days.

CNS Pharmaceuticals Stock Performance

Shares of NASDAQ:CNSP remained flat at $0.14 during mid-day trading on Friday. 670,562 shares of the company were exchanged, compared to its average volume of 2,014,493. The company has a market cap of $203,318.70, a price-to-earnings ratio of 0.00 and a beta of 2.58. The stock has a fifty day moving average of $0.28 and a 200 day moving average of $6.04. CNS Pharmaceuticals has a 1-year low of $0.10 and a 1-year high of $137.50.

CNS Pharmaceuticals (NASDAQ:CNSP) last announced its earnings results on Wednesday, August 14th. The company reported ($6.72) EPS for the quarter.

Institutional Trading of CNS Pharmaceuticals

A hedge fund recently raised its stake in CNS Pharmaceuticals stock. Virtu Financial LLC boosted its stake in shares of CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) by 616.6% during the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 94,246 shares of the company’s stock after buying an additional 81,094 shares during the period. Virtu Financial LLC owned approximately 0.80% of CNS Pharmaceuticals worth $34,000 as of its most recent filing with the SEC. Institutional investors and hedge funds own 14.02% of the company’s stock.

Analyst Ratings Changes

Separately, Maxim Group upgraded shares of CNS Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 price target on the stock in a research report on Tuesday, September 10th.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.